Your shopping cart is currently empty

DHFR-IN-17 (compound j9) is an orally active SaDHFR inhibitor with an IC50 value of 0.97 nM. It exhibits antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration of 0.031 μg/mL.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | DHFR-IN-17 (compound j9) is an orally active SaDHFR inhibitor with an IC50 value of 0.97 nM. It exhibits antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration of 0.031 μg/mL. |
| In vivo | DHFR-IN-17 (compound j9), when administered orally at doses of 2, 5, or 10 mg/kg for three consecutive days, helps alleviate skin infection damage in C57 mice caused by MRSA induction. |
| Formula | C17H21IN4O2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.